

21741

## THE WATEDWETATES PATENT AND TRADEMARK OFFICE

In re Application of : Michael Cawthorne, et al.

Serial No. : 10/019,139

RECEIVED

Filing Date

RECEIVED

NOV 0 6 2003

Examiner

OC1 3 0 7003

Not yet assigned

May 20, 2002

Group Art UnitGROUP 1700

1741

TECH CENTER 1600/2900

Entitled

METHODS AND COMPOSITIONS RELATING TO PANCREATIC ISLET

AND B-CELL DYSFUNCTION

------

Suite 2400

1601 Market Street Philadelphia, PA 19103

(215) 563-4100 (telephone) (215) 563-4044 (facsimile)

Our File No. 0380-P02773US0

## Certificate of Mailing Under 37 C.F.R. §1.8(a):

I hereby certify that this correspondence is being deposited on <u>Other 14,2003</u> with the United States Postal Service as first-class mail in an envelope properly addressed to the Mail Stop, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Lynn C. Fischer

Mail Stop Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.56

Dear Sir:

In compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith a Form PTO-1449 and a copy of the references listed thereon. This

Information Disclosure Statement is being filed more than three (3) months after the filing date, but before receipt of the first Official Action on the merits. Thus, it is believed by the undersigned attorney that no fee is required under 37 C.F.R. §1.97(b).

Applicants wish to call the Examiner's attention to their co-pending U.S. patent applications, serial numbers 10/070,081 and 09/980,422.

Several references listed on the Form PTO-1449 were also listed on the International Search Reports of this application and the co-pending U.S. patent applications 10/070,081 and 09/980,422. The U.S. Patent and Trademark Office has already received the references listed in the International Search Reports as indicated on the Form PCT/DO/EO/903 (371 Acceptance Notice) in each application. Those references are listed on the Form 1449 as A14 and A15, B6, B7, B9, B9, and B10, and also C19, C20, C21, C22, C23 and C24.

In the event that a fee is required, the Commissioner is authorized to charge Deposit Account No. 04-1406 of the undersigned attorneys. A duplicate copy of this sheet is enclosed.

In the opinion of the undersigned, the references submitted herewith are the most pertinent of which the undersigned is aware. However, no representation is made or intended that more pertinent references do not exist.

This submission is not an admission that the references listed on the attached Form PTO-1449 constitute prior art against the claims of this application.

The Examiner is respectfully requested to confirm receipt and consideration of the cited references by initialing and returning a copy of the attached Form PTO-1449 in accordance with M.P.E.P. §609.

Early and favorable consideration of this application is respectfully requested.

DANN DORFMAN HERRELL and SKILLMAN, P.C.


Attorneys for Applicant

Ву

Patrick J. Hagan

Registration No. 27,643

PJH:lcf Enclosures



		UNITED STATES PATENT DOCUMENTS TECH CENTER		
EXAMINER'S INITIALS	CITE NO.	PATENT NUMBER	ISSUE DATE MM-DD-YYYY	FIRST NAMED INVENTOR
	A1	5,702,902	12-30-1997	Tartaglia
	A2	5,849,578	12-15-1998	Falb
	A3	5,846,824	12-08-1998	Hiles
	A4	5,840,504	11-24-1994	Blecher
	A5	5,837,116	11-17-1998	Harrington
	A6	5,773,645	06-30-7998	Hochstrasser
	A7	5,716,787	02-10-1998	Dunn
	A8	5,562,813	10-08-1996	Mullaart
	· <b>A</b> 9	5,407,546	04-18-1995	Schickle
	A10	4,874,490	10-17-1989	Hochstrasser
	A11	4,824,547	04-25-1989	Zhang
	A12	4,666,581	05-19-1987	ltoh
_	A13	5,789,651	08-04-1998	Woychik
	A14	5,861,485 A	01-19-1999	Tartaglia
	A15	5,795,726 A	08-18-1998	Glucksmann M. Alexandra

FOREIGN PATENT DOCUMENTS					
EXAMINER'S INITIALS	CITE NO.	DOCUMENT NUMBER	COUNTRY OR REGION	DATE OF PUBLICATION MM-DD-YYYY	FIRST NAMED INVENTOR OR APPLICANT
	B1	WO 96/05861A1	PCT	02-29-1996	Millenium Pharmaceuticals
	B2	WO 98/19271	PCT	05-07-1998	Mose Larsen, et al.
	В3	WO 98/20124	PCT	05-14-1998	Mose Larsen, et al.
	B4	WO 99/41612	PCT	08-19-1999	Oxford Glycosciences
	B5	WO 99/47925	PCT	09-23-1999	Oxford Glycosciences

EXAMINER'S	DATE
SIGNATURE	CONSIDERED

**EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



## Complete if known

Application Number: 10/019,139

NOV 0 6 2003

Filing Date: May 20, 2002

LECH CENTER 1600/20

First Named Inventor: Michael Cawthorne, et al.

Group Art Unit: 1741

RECEIVED

Examiner Name: Not yet assigned

<del>90+3 a zana</del>

Our File No. 0380-P02773US0

GROUP 1700

B6	WO 00/46369 A	PCT	08-10-2000	Chiron Corp.
B7	WO 97/15310 A	PCT	05-01-1997	University Florida Research Foundation
B8	WO 00/46404 A	PCT	08-10-2000	Das Rina, Jett Marti, et al.
B9	WO 00/32779 A	PCT	06-08-2000	Leptin Maria
B10	WO 00/32618 A	PCT	06-08-2000	Exelixis Pharmaceuticals Inc.

INFORMATION

STATEMENT

SHEET


2

OF 4

OTHER PRIOR ART - NON-PATENT DOCUMENTS				
EXAMINER'S INITIALS	CITE NO.	Include name of the author (in Capital Letters), title of the article (when appropriate), title of the item(book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		
	C1	DONNELLY, RICHARD, et al., "Mechanisms of Insulin resistance and new pharacological approaches to metabolism and diabetic complications"; Clin. Exp. Pharamcol. & Physiol., 25: 79-87 (1998)		
	C2	LYNCH, CHRISTOPHER J., et al., "Carbonic anhydrase III in obese Zucker rats"; Am. J. Physiol. 264: E621-E630 (1993)		
	С3	LYNCH, CHRISTOPHER J., et al., "Pyruvate caroxylase in genetic obesity"; Am. J. Physiol. 262: E608-E618 (1992)		
•	C4	BLACKSHEAR, PERRY J., et al., "Evidence against Insulin-stimulated Phosphorylation of Calmodulin in 3T3-L1 Adipocytes"; J. Biol. Chem., 264: 3854-3858 (1989)		
. C5		SADOWSKI, HENRY B., et al., "Gene Expression During 3T3-L1 Adipocyte Differentiation"; J. Biol. Chem., 266: 4722-4731 (1992)		
	C6	ANDERSON, N. LEIGH, et al., "The Effects of Peroxisome Proliferators on Protein Abundances in Mouse Liver"; Toxicology and Applied Pharmacology, 137: 75-89 (1996)		
	C7	ANDERSEN, HENRIK U., et al., "Interleukin-1β induced changes in the protein expression of rat islets: a computerized database"; Electrophoresis 18: 2091-2103 (1997)		
	C8	ROSSIER, JOEL S., et al., "Microchannel networks for electrophoretic separations"; electrophoresis 20: 727-731 (1999)		
	C9	Conference: "Improved management of obesity and non-insulin dependent diabetes mellitus & novel drug developments"; Royal College of Pathologists, London, April 19-20 (1999)		
	C10	Conference: "Novel drug developments for NIDDM & insulin resistance"; Royal College of Pathologists, London, April 21 (1999)		
-	C11	NORDHOFF, ECKHARD, et al., "Rapid identification of DNA-binding proteins by mass spectrometry"; Nat. Biotech., 17: 884-888 (1999)		

ir	
EXAMINER'S	DATE
SIGNATURE	CONSIDERED
O TOTAL TOTAL	- CONTRIBETION


**EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



C12	ANDERSEN, HENRIK U., et al., "Two-dimensional gel electrophoresis of rat islet proteins"; Diabetes, 44: 400-407 (1995)
C13	LARSEN, MOSE, et al., Meeting abstract, Electrophoresis conference, Siena, Italy, "Towards understanding diabetes at the molecular level"; Oral Parallel Session 2 - Rat and Mouse p. 135 (1998)
C14	EDVARDSSON, U., et al., Meeting abstact, Electrophoresis conference, Siena, Italy, "A proteomics analysis of livers from obese (OB/OB) mice treated with the ppar agonists WY14,643 and BRL49653"; Oral Parallel Session 2 - Rat and Mouse, p. 136 (1998)
C15	SANCHEZ, JEAN-CHARLES, "Proteomic studies in obesity and NIDDM"; Abstract of presentation given at 4 <sup>th</sup> International Clore Symposium, Buckingham, UK, July 1, 1999
C16	SANCHEZ, JEAN-CHARLES, et al., "Effect of rosiglitazone on the differential expression of diabetes and obesity associate proteins in ob/ob mice: molecular targets of insulin sensitisation"; abstract of poster presentation at Keystone Symposium on Diabetes Mellitus: February 20, 2000, Taos, New Mexico, USA
C17	SANCHEZ, JEAN-CHARLES, et al., "Effect of rosiglitazone on the differential expression of diabetes associated proteins in pancreatic islets of C57B1/6J lep/lep mice"; presentation at American Diabetes Association Conference, San Antonio, USA, June 20, 2000; Diabetes 49, Supplement 1, Abs 1041-P, A250
C18	SANCHEZ, JEAN-CHARLES, et al., "Using proteomics to identify islet targets"; abstract of presentation given at IBC Conference on NIDDM, London, UK April 4, 2000
C19	EDVARDSSON, U., et al., "A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643." Electrophoresis, 20:935-942, (1999)
. C20	SHIMADA, A., et al., "Beta-cell destruction may be a late consequence of the autoimmune process in nonobese diabetic mice"; Diabetes, 45:1063-1067 (1996).
C21	JITRAPAKDEE, S., et al., "Regulation of rat pyruvate carboxylase gene expression by alternative promoters during development, in genetically obese rats and in insulin-secreting cells: Multiple transcripts with 5'-end heterogeneity modulate translation."; J. of Biological Chemistry, 273: 34422-34428 (1998).
C22	STANTON, L.W., et al., "Expression of CA III in rodent models of obesity"; Molecular Endocrinology, 5: 860-866, (1991).
C23	LEE, R.I., et al., "Cloning and characterization of a 35-kDa mouse mitochondrial outer membrane protein MOM35 with high homology to Tom40." J. of Bioenergetics and Biomembranes, 32: 111-121 (2000).

EXAMINER'S	DATE	
SIGNATURE	CONSIDERED	

**EXAMINER**: Initial if reference considered, whether or not citation is in conformance with MPEP §609. Draw a line through citation if citation not in conformance and reference not considered. Include a copy of this form with next communication to applicant.



C2
----

	<u>,                                    </u>	<del></del>	
EXAMINER'S		DATE	
SIGNATURE		CONSIDERED	